Keros completes Phase 1 Clinical Trial
Keros Therapeutics has provided an update on their lead drug for FOP, KER-047. Keros has completed its first set of clinical trials (Phase 1) in healthy individuals and KER-047 was shown to be well tolerated.
They are now planning their Phase 2 clinical trial with KER-047 in people with FOP in the first half of 2021. Keros is also studying whether KER-047 can help people with a form of anemia (or low blood cells).
Read more about Keros and their FOP drug development program